OSTM1-AS1: A Potential Drug Target and Biomarker (G100287366)

Target Name: OSTM1-AS1

NCBI ID: G100287366

OSTM1-AS1

Other Name(s): OSTM1 antisense RNA 1 (non-protein coding) | OSTM1 antisense RNA 1

OSTM1-AS1: A Potential Drug Target and Biomarker

The OSTM1 gene, located on chromosome 6p21.1, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The OSTM1 gene has been shown to regulate various cellular processes that are crucial for normal cell function, including cell signaling, migration, and survival.

Disease-Causation Relationships

Studies have suggested that disruptions in OSTM1 gene function contribute to the development and progression of various diseases. For example, OSTM1 has been linked to the development of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases, as well as cancer.

In addition, OSTM1 has been shown to be involved in the regulation of immune responses, which is critical for maintaining cellular health and preventing disease. Dysregulation of OSTM1 has been implicated in the development of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

Potential Drug Targets

The OSTM1 gene has been identified as a potential drug target due to its involvement in various cellular processes that are crucial for normal cell function. One potential drug target is the OSTM1 gene itself, as inhibitors of OSTM1 have been shown to cause cellular death and disrupt cellular processes that are necessary for normal cell survival.

Another potential drug target is the OSTM1 gene's downstream targets, such as the FBN1 gene, which has been shown to interact with OSTM1 and is involved in the regulation of blood clotting. OSTM1 inhibitors have been shown to disrupt FBN1 function and increase the risk of blood clots, making them a potential treatment for cardiovascular disease.

Biomarkers

ASTM1, a protein produced by OSTM1, has been shown to be a potential biomarker for various diseases, including cancer. ASTM1 has been shown to be involved in the regulation of cell growth, apoptosis, and angiogenesis, which are critical for the development and progression of cancer.

In addition, ASTM1 has been shown to be involved in the regulation of immune responses, which is critical for maintaining cellular health and preventing disease. Dysregulation of ASTM1 has been implicated in the development of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

Molecular Mechanisms

The OSTM1 gene has been shown to play a crucial role in the regulation of various cellular processes that are crucial for normal cell function. The OSTM1 gene has been shown to regulate the expression of several genes involved in cell signaling, including TGF-β1, NF-kappa-B, and AP-1.

In addition, the OSTM1 gene has been shown to regulate the expression of genes involved in cell migration and survival, including the KLF gene. KLF is a key regulator of longevity and has been shown to interact with OSTM1 to promote cellular survival and proliferation.

Conclusion

In conclusion, OSTM1-AS1 is a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The OSTM1 gene has been shown to regulate various cellular processes that are crucial for normal cell function, and disruptions in OSTM1 function have been implicated in the development and progression of various diseases. Further research is needed to fully understand the role of OSTM1 in disease and to develop effective treatments.

Protein Name: OSTM1 Antisense RNA 1

The "OSTM1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OSTM1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets